Skip to main content
. 2023 Nov 30;20(17):1151–1164. doi: 10.2217/fon-2022-1315

Figure 3.

Figure 3.

Second-line treatment regimens for extensive-stage small cell lung cancer in EU5 between 2018 and 2021*.

*Regimens that contributed <2% individually to total percentage from 2018 to 2021 are not shown. Consequently, percentages do not add up to 100% in each analyzed year.

Cyc/Dox/Vinc: Cyclophosphamide, doxorubicin and vincristine combination chemotherapy.